Atlas Trials

Esanex Inc.

12 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Esanex Inc.

RecordFirmDate
Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL (NCT02973399)Esanex Inc.2017-02-07
Safety and Activity of SNX-5422 Plus Ibrutinib in CLL (NCT02914327)Esanex Inc.2017-02-02
Study of SNX-5422 in TP53 Null Cancers (NCT02612285)Esanex Inc.2016-03-01
Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors (NCT02063958)Esanex Inc.2014-02-01
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies (NCT01635712)Esanex Inc.2014-02-01
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors (NCT01892046)Esanex Inc.2013-11-01
Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers (NCT01848756)Esanex Inc.2013-04-01
Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma (NCT01851096)Esanex Inc.2013-03-01
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies (NCT01611623)Esanex Inc.2012-05-01
Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas (NCT00647764)Esanex Inc.2008-03-01
Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies (NCT00595686)Esanex Inc.2008-01-01
Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies (NCT00506805)Esanex Inc.2007-06-01

Track Esanex Inc. automatically

Every clearance here is in the API, with alerts when new ones post.